Article Details
Retrieved on: 2023-01-09 20:11:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
This deal would bolster AstraZeneca's portfolio of heart and kidney drugs. CinCor's experimental therapy baxdrostat has been a strong selling point ...
Article found on: pulse2.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here